Nurix Therapeutics根据纳斯达克上市规则5635(c)报告诱导性赠款-动脉网

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 等信源发布 2025-03-14 16:00



可切换为仅中文







SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on March 11, 2025, the company granted inducement awards to thirteen new employees.

旧金山，2025年3月14日（环球新闻社）-- Nurix Therapeutics, Inc.（纳斯达克股票代码：NRIX），一家处于临床阶段的生物制药公司，专注于发现、开发和商业化靶向蛋白质降解药物，这是创新药物设计的下一个前沿领域，旨在改善癌症和炎症疾病患者的治疗选择。该公司今天宣布，在2025年3月11日，向十三名新员工授予了入职奖励。

The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4)..

根据Nurix的2024年股权激励计划，这些授予作为员工接受Nurix工作邀请的重要诱因，并已由Nurix董事会薪酬委员会依据纳斯达克上市规则5635(c)(4)批准。

The company granted stock options to purchase an aggregate of 157,150 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 107,500 shares of Nurix common stock.

公司授予了可购买总计157,150股Nurix普通股的股票期权，以及代表总计107,500股Nurix普通股的限制性股票单位奖励（RSUs）。

One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee’s date of hire, subject to the employee’s continued service with Nurix on each such vesting date.

股票期权对应的总股数的四分之一将于员工入职日期的一周年时归属，此后每月将归属股票期权对应总股数的四十八分之一，直至股票期权在员工入职日期的四周年时完全归属，但前提是员工在每次归属日时仍持续为Nurix提供服务。

The stock options have a term of ten years and an exercise price of $13.90 per share, which is equal to the closing price of Nurix’s common stock on the grant date as reported by the Nasdaq Global Market..

股票期权的期限为十年，每股行使价格为 13.90 美元，等于纳斯达克全球市场报告的授予日 Nurix 普通股的收盘价。

One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee’s continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee’s continued service with Nurix on each such vesting date..

受限股票单位（RSUs）所涉及的总股数的四分之一将于RSU归属起始日期的一周年，即2025年4月30日归属，前提是员工在归属日期当天仍继续为Nurix服务。此后，受限股票单位所涉及的总股数的十六分之一将按季度归属，直至RSU奖励在归属起始日期的四周年时完全归属，前提是员工在每个此类归属日期当天仍继续为Nurix服务。

About Nurix Therapeutics, Inc.

关于Nurix Therapeutics公司

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.

Nurix Therapeutics是一家临床阶段的生物制药公司，专注于发现、开发和商业化靶向蛋白质降解药物，这是创新药物设计的下一个前沿领域，旨在改善癌症和炎症疾病患者的治疗选择。

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline.

Nurix全资拥有的临床阶段管线包括布鲁顿酪氨酸激酶（BTK）降解剂，BTK是一种B细胞信号蛋白，以及Casitas B系淋巴瘤原癌基因B（CBL-B）抑制剂，CBL-B是一种调节多种免疫细胞类型（包括T细胞和NK细胞）活化的E3连接酶。Nurix还在其临床前管线中推进多种潜在的首创或最佳降解剂及降解剂抗体偶联物（DAC）。

Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates.

Nurix的合作药物发现管线包括处于临床前阶段的IRAK4和STAT6降解剂，以及与吉利德科学公司、赛诺菲集团和辉瑞公司合作的多个项目，在这些合作中，Nurix保留了在美国对多种候选药物进行共同开发、共同商业化和利润分享的特定选择权。

Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

凭借一个完全集成人工智能的发现引擎，能够应对任何蛋白质类别，并结合无与伦比的连接酶专业知识，Nurix 的专业团队在将靶向蛋白质降解的科学转化为临床进展方面建立了强大的优势。Nurix 旨在将基于降解剂的治疗方法置于患者护理的前沿，用一种新方案书写医学的下一篇章，以战胜疾病。

Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com..

Nurix总部位于加利福尼亚州旧金山。欲了解更多信息，请访问http://www.nurixtx.com。

Contacts:

联系人：

Investors

投资者

Jason Kantor, Ph.D.

杰森·康托尔，哲学博士

Nurix Therapeutics, Inc.

ir@nurixtx.com

Elizabeth Wolffe, Ph.D.